MEDX.F Stock Overview
Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Medexus Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.28 |
| 52 Week High | CA$2.56 |
| 52 Week Low | CA$0.84 |
| Beta | 1.85 |
| 1 Month Change | 4.59% |
| 3 Month Change | -27.62% |
| 1 Year Change | 21.43% |
| 3 Year Change | -79.10% |
| 5 Year Change | -62.94% |
| Change since IPO | -65.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| MEDX.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -1.9% | 3.0% | -0.7% |
| 1Y | 21.4% | 12.5% | 22.8% |
Return vs Industry: MEDX.F exceeded the US Pharmaceuticals industry which returned 11.6% over the past year.
Return vs Market: MEDX.F matched the US Market which returned 22.3% over the past year.
Price Volatility
| MEDX.F volatility | |
|---|---|
| MEDX.F Average Weekly Movement | 13.2% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MEDX.F's share price has been volatile over the past 3 months.
Volatility Over Time: MEDX.F's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 98 | Ken d'Entremont | www.medexus.com |
Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Medexus Pharmaceuticals Inc. Fundamentals Summary
| MEDX.F fundamental statistics | |
|---|---|
| Market cap | US$32.35m |
| Earnings (TTM) | US$5.88m |
| Revenue (TTM) | US$115.73m |
5.3x
P/E Ratio0.3x
P/S RatioIs MEDX.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MEDX.F income statement (TTM) | |
|---|---|
| Revenue | US$115.73m |
| Cost of Revenue | US$48.91m |
| Gross Profit | US$66.81m |
| Other Expenses | US$60.93m |
| Earnings | US$5.88m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.24 |
| Gross Margin | 57.73% |
| Net Profit Margin | 5.08% |
| Debt/Equity Ratio | 174.9% |
How did MEDX.F perform over the long term?
See historical performance and comparison